Warren, New Jersey, August 24, 2026
PTC Therapeutics, Inc. announced that new clinical and real-world evidence for Sephience™ (sepiapterin) will be presented at the 2026 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in Helsinki, Finland, from August 25–28. The company plans 17 abstracts and presentations focused on Sephience and its potential benefits for people living with phenylketonuria (PKU). The new data emphasize blood phenylalanine reduction, sustained metabolic control and dietary liberalization, including findings from patients with high baseline phenylalanine levels and different PKU subgroups. For cGxP.wire, the key development is the growing body of clinical and real-world evidence supporting Sephience as a treatment option aimed at improving metabolic management while potentially reducing the dietary burden associated with PKU.
Sephience Data Focus on Metabolic Control
New analyses from the AMPLIPHY study are among the data being highlighted at SSIEM 2026. According to PTC Therapeutics, participants who were receiving sapropterin at screening experienced a 100% greater reduction in blood phenylalanine after switching to Sephience. Additional analyses evaluated participants with high baseline blood Phe levels of at least 900 µmol/L, with treatment producing clinically meaningful reductions within 14 days. The company reported response rates comparable to those observed in the overall study population, while the safety findings remained consistent with previous Sephience studies. These results are particularly relevant to the broader PKU treatment landscape because they provide evidence from patients with substantial baseline metabolic burden rather than limiting the analysis to individuals with lower Phe concentrations. The findings also support continued evaluation of Sephience across a broad spectrum of patients with PKU.
Real-World Evidence Supports Diet Liberalization
Another important area of the SSIEM presentations is real-world evidence showing dietary liberalization among adolescents treated with Sephience. PTC Therapeutics reported that patients were able to significantly broaden their diets while maintaining blood phenylalanine levels within recommended targets. The company said the findings were observed in individuals with both BH4-responsive and classical/non-BH4-responsive PKU mutations. This aspect is particularly important for cGxP.wire because dietary management remains a central component of PKU care, and the ability to expand dietary choices while maintaining metabolic control could affect treatment burden and independence for patients and families. Sephience is a precursor of the BH4 cofactor, which is involved in phenylalanine hydroxylase activity, and is intended to lower circulating Phe levels in responsive patients. The new evidence therefore adds a practical treatment dimension beyond simply measuring biochemical changes.
Advertisement
Broad PKU Benefits Supported by New Evidence
PTC Therapeutics said the SSIEM data continue to demonstrate benefits across different patient subgroups, including individuals with classical PKU and those with high baseline Phe concentrations. Sephience is indicated for adult and pediatric patients aged 1 month and older with sepiapterin-responsive PKU, and treatment is used alongside a Phe-restricted diet. The company also continues to report a consistent safety profile across its clinical development program. Important safety considerations include bleeding risk and hypophenylalaninemia, requiring appropriate monitoring of patients and blood Phe levels, particularly in pediatric populations. PKU is a rare inherited metabolic disorder in which the body cannot adequately process phenylalanine, allowing Phe to accumulate to potentially harmful levels. The latest SSIEM evidence keeps the focus on whether Sephience can deliver rapid Phe reduction, sustained metabolic control and meaningful dietary flexibility, making the upcoming scientific presentations an important update for clinicians and the rare-disease community.
Source:PTC Therapeutics, press relese
